FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Sara Grethlien, MD, MBA, FACP, Swedish Cancer Institute, looks ahead to the future of oncology care and important value-based care considerations.

Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic ...

Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who ...

This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of ...

According to Ian Neeland, MD, strategies like pharmacist-led counseling, patient education programs, and patient assistance ...

The individual behavior of a patient’s myeloproliferative neoplasm (MPN) will determine how the disease is monitored and ...